Eastern Bank’s Kymera Therapeutics KYMR Stock Holding History

Eastern Bank’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-74	Closed	-$6.16K	–	1126
2026 Q1	$6.16K	Hold	74	–	–	﹤0.01%	913
2025 Q4	$5.76K	Buy	+74	New	+$5K	﹤0.01%	947

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Eastern Bank's KYMR Position: Q2 2026 in Review

Eastern Bank sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 74 shares — an estimated $6.16K sold.

Eastern Bank first reported a position in KYMR in Q4 2025 and held it in 2 quarters. The position peaked at $6.16K in Q1 2026. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Eastern Bank reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
Eastern Bank sold 74 Kymera Therapeutics shares in Q2 2026, an estimated $6.16K.
Eastern Bank first reported a position in Kymera Therapeutics in Q4 2025 and held it in 2 quarters.
Eastern Bank's Kymera Therapeutics position peaked at $6.16K in Q1 2026.
277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Eastern Bank's 13F filing for Q2 2026, filed 1 Jul 2026.